

THE LANCET

Rheumatology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Saxena A, Guttman A, Masson M, et al. Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. *Lancet Rheumatol* 2021; published online May 27. [https://doi.org/10.1016/S2665-9913\(21\)00114-4](https://doi.org/10.1016/S2665-9913(21)00114-4).

APPENDIX METHODS

All patients in the WARCOV cohort were age 18 years or older and had SLE fulfilling at least 1 of the following criteria sets: 1) the American College of Rheumatology (ACR) revised classification criteria^{1,2}; 2) the Systemic Lupus International Collaborating Clinics classification criteria³; 3) the European League Against Rheumatism/ACR classification criteria⁴ or had been diagnosed by a rheumatologist as having SLE (if fulfillment of classification criteria for SLE could not be confirmed due to incomplete or unavailable data). Only English-, Spanish- or Mandarin-speaking patients were included in the study.

The NYU Lupus Cohort is a prospective convenience registry open to enrollment of any patient with SLE seen at NYU Langone Health and NYC Health + Hospitals/Bellevue since 2014. All SLE patients in the NYU Lupus Cohort are age 18 or older and fulfill at least one of the following criteria for SLE: 1) the American College of Rheumatology (ACR) revised classification criteria^{1,2}; 2) the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria³; 3) the European League Against Rheumatism (EULAR)/ACR classification criteria.⁴ All patients and controls signed an informed consent to be in the NYU Lupus Cohort. NYU Lupus Cohort consents are available in English, Spanish and Mandarin.

An additional 15 SARS-CoV-2 IgG tests were evaluated using the DiaSorin Liaison® SARS-CoV-2 S1/S2 IgG assay, 28 tests were performed at an outside lab that utilized either the Abbott Architect, Ortho Clinical Diagnostics or EuroImmun assays, 2 tests were conducted using the Elecsys® anti-SARS-CoV2 immunoassay, 1 test was performed using the ARUP qualitative chemiluminescent immunoassay, 1 test used the polyvalent microsphere immunofluorescence assay for IgG/IgM/IgA through the New York State Department of Health, and 1 test was conducted using an unknown assay at a University Hospital.

REFERENCES

- 1 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1997; **40**: 1725.
- 2 Tan EM, Cohen AS, Fries JF, *et al.* The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982. DOI:10.1002/art.1780251101.
- 3 Petri M, Orbai AM, Alarcón GS, *et al.* Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012. DOI:10.1002/art.34473.
- 4 Aringer M, Costenbader K, Daikh D, *et al.* 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol* 2019. DOI:10.1002/art.40930.

SUPPLEMENTARY TABLES

Supplementary Table 1. SARS-CoV-2 IgG in COVID-19 RT-PCR positive SLE patients.

Case	Age Range (y)	Sex	Ethnicity/Race	Time from COVID-19 RT-PCR to first Ab test (wks)	Concurrent medications	COVID-19 hospitalization	Highest Ab Titer (Abbot Architect) (nl <1.4 s/c)
Negative SARS-CoV-2 IgG							
1	>20-25	F	NH/O	24.1	HCQ	N	1.2
2	>55-60	F	H/B	6.4	HCQ, Prednisone (10 mg/day)	N	0.8
3	>55-60	F	NH/B	7.1	HCQ, MMF, Tacrolimus, Prednisone (5 mg/day)	Y	1.0
4	>35-40	F	H/W	21.3	HCQ, Cyclophosphamide, Prednisone (5 mg/day)	Y	1.2
5	>35-40	M	H/W	10.3	HCQ, MMF, Obinutuzumab	Y	0.1
Positive SARS-CoV-2 IgG							
1	>35-40	F	NH/A	6.0	HCQ, Prednisone	N	N/A
2	>50-55	F	NH/W	9.6	Anakinra, Cyclosporine	N	3.3
3	>30-35	F	NH/W	5.1	HCQ, Azathioprine	N	1.8
4	>20-25	F	H/O	30.3	HCQ, Azathioprine, Prednisone	N	2.4
5	>35-40	F	NH/B	17.0	HCQ, MMF	N	4.0
6	>50-55	M	NH/B	14.7	HCQ	N	N/A
7	>30-35	F	NH/W	6.4	HCQ	N	N/A
8	>40-45	F	NH/W	24.4	HCQ, Abatacept	N	N/A
9	>85-80	F	H/W	24.7	HCQ	N	6.4
10	>35-40	F	NH/O	4.6	HCQ	N	7.7
11	>35-40	F	NH/B	5.7	HCQ, Cyclophosphamide, Rituximab, Prednisone	N	8.1
12	>25-30	F	H/W	10.9	HCQ, Belimumab	N	2.0
13	>20-25	F	NH/W	0	HCQ, Azathioprine, Rituximab	N	N/A
14	>55-60	F	NH/B	18.0	HCQ	N	7.4
15	>50-55	F	NH/B	19.1	HCQ	N	1.8
16	>45-50	F	NH/B	3.3	HCQ, MMF, Prednisone	N	4.3
17	>30-35	F	NH/W	3.7	HCQ, Prednisone	N	N/A
18	>45-50	F	NH/B	9.0	MMF, Belimumab	Y	3.6
19	>50-55	F	H/B	5.9	HCQ, MMF, Prednisone	Y	6.9
20	>35-40	F	NH/B	8.0	HCQ, MMF, Prednisone	Y	4.8
21	>65-70	F	H/W	22.4	HCQ, Methotrexate, Belimumab	Y	4.1
22	>65-70	F	H/W	26.6	None	Y	3.9
23	>25-30	F	NH/B	21.0	HCQ, MMF	Y	3.6
24	>55-60	F	NH/A	1.7	HCQ, Rituximab	Y	7.4

A, Asian race; Ab, Antibody; B, Black race; COVID-19, Coronavirus disease 2019; F, Female; H, Hispanic; HCQ, Hydroxychloroquine; IgG, Immunoglobulin G; IVIG, Intravenous immunoglobulin; M, Male; MMF, Mycophenolate mofetil; N/A, not available; NH, Not Hispanic; NI, Normal; NYU, New York University; O, Other race; RT-PCR, real-time reverse transcriptase polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S/c, Specimen calibrator; SLE, Systemic Lupus Erythematosus; W, White race; Wks, Weeks; Y, years.

Supplementary Table 2. Positive SARS-CoV-2 IgG SLE patients with unknown COVID-19 symptoms and no RT-PCR (NYU Lupus Cohort).

Case	Age Range (y)	Sex	Ethnicity/Race	Concurrent medications	COVID-19 hospitalization	Highest Ab Titer (Abbot Architect) (nl <1.4 s/c)
1	>30-35	F	NH/B	HCQ, MMF, Tacrolimus	N	3.6
2	>35-40	F	NH/W	HCQ, MMF, Prednisone	N	2.7
3	>25-30	F	H/O	HCQ, MMF, Prednisone	N	3.7
4	>30-35	F	H/A	HCQ, Azathioprine	N	3.9
5	>75-80	M	H/W	HCQ, Prednisone	N	6.4
6	>60-65	F	NH/B	HCQ	N	5.7
7	>30-35	F	NH/B	None	N	N/A
8	>55-60	F	H/W	HCQ, Methotrexate	N	10.6
9	>30-35	F	H/W	HCQ, MMF, Tacrolimus, Prednisone	N	1.7
10	>60-65	F	H/W	HCQ	N	3.7
11	>18-20	F	NH/W	HCQ	N	5.3
12	>40-45	F	H/W	HCQ, MMF, Prednisone	N	2.0
13	>45-50	F	NH/B	HCQ, MMF, Prednisone	N	3.9
14	>60-65	M	H/W	HCQ, Cyclophosphamide	N	2.1
15	>70-75	F	H/W	HCQ, Leflunomide	N	3.2
16	>25-30	F	H/W	HCQ, MMF, Belimumab, Prednisone	N	5.7

A, Asian race; Ab, Antibody; B, Black race; COVID-19, Coronavirus disease 2019; F, Female; H, Hispanic; HCQ, Hydroxychloroquine; IgG, Immunoglobulin G; IVIG, Intravenous immunoglobulin; M, Male; MMF, Mycophenolate mofetil; N/A, not available; NH, Not Hispanic; NI, Normal; NYU, New York University; O, Other race; RT-PCR, real-time reverse transcriptase polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S/c, Specimen calibrator; SLE, Systemic Lupus Erythematosus; W, White race; Wks, Weeks; Y, years.

Supplementary Table 3. All SLE patients evaluated for SARS-CoV-2 IgG (with Abbot Architect platform titer if available)

Age Range (y)	Sex	Ethnicity	Race	HCQ	IS	Pred	SARS-CoV-2 IgG Ab +	Ab Titer (s/c)
>55-60	F	H	W	Y	Y	N	Y	10.59
>35-40	F	NH	B	N	Y	Y	Y	8.10
>35-40	F	NH	O	Y	N	N	Y	7.70
>55-60	F	NH	B	Y	N	N	Y	7.40
>55-60	F	NH	A	Y	Y	N	Y	7.40
>50-55	F	H	B	Y	Y	Y	Y	6.90
>75-80	M	H	W	Y	N	Y	Y	6.40
>85-90	F	H	W	Y	N	N	Y	6.40
>20-25	F	H	W	Y	Y	Y	Y	5.70
>55-60	F	NH	B	Y	N	N	Y	5.70
>18-20	F	NH	W	Y	N	N	Y	5.30
>18-20	F	H	W	Y	Y	N	Y	4.90
>35-40	F	NH	B	Y	Y	Y	Y	4.80
>45-50	F	NH	B	Y	Y	Y	Y	4.36
>65-70	F	H	W	Y	Y	N	Y	4.10
>35-40	F	NH	B	Y	Y	N	Y	4.00
>65-70	F	H	W	N	N	N	Y	3.90
>30-35	F	H	A	Y	Y	N	Y	3.90
>45-50	F	NH	B	Y	Y	Y	Y	3.90
>60-65	F	H	W	Y	N	N	Y	3.70
>20-25	F	H	O	Y	Y	Y	Y	3.70
>25-30	F	NH	B	Y	Y	N	Y	3.60
>45-50	F	NH	B	N	Y	Y	Y	3.60
>30-35	F	NH	B	Y	Y	N	Y	3.60
>50-55	F	NH	W	N	Y	N	Y	3.30
>70-75	F	H	W	Y	Y	N	Y	3.20
>60-65	F	H	B	Y	Y	N	Y	3.09
>30-35	F	NH	B	Y	N	N	Y	3.00
>45-50	F	H	O	Y	N	N	Y	3.00
>35-40	F	NH	W	Y	Y	Y	Y	2.50
>20-25	F	H	O	Y	Y	Y	Y	2.40
>40-45	F	NH	B	Y	N	N	Y	2.30
>25-30	F	H	W	Y	N	N	Y	2.20
>35-40	F	H	W	Y	N	N	Y	2.19
>60-65	M	H	W	Y	Y	N	Y	2.11
>30-35	F	H	W	Y	Y	Y	Y	2.10
>25-30	F	H	W	Y	Y	N	Y	2.00
>40-45	F	H	W	Y	Y	Y	Y	2.00

>25-30	F	NH	W	Y	Y	N	Y	1.80
>40-45	F	H	B	N	N	N	Y	1.80
>50-55	F	NH	B	Y	N	N	Y	1.80
>30-35	F	H	W	Y	Y	Y	Y	1.70
>55-60	M	NH	A	N	Y	N	N	0.14
>45-50	F	NH	W	Y	Y	N	N	0.00
>50-55	F	NH	W	Y	N	N	N	0.10
>35-40	M	H	B	Y	Y	N	N	1.30
>20-25	F	NH	O	Y	N	N	N	1.20
>30-35	F	NH	W	Y	N	N	N	1.20
>40-45	F	H	W	Y	Y	Y	N	1.19
>35-40	F	H	W	Y	Y	Y	N	1.17
>35-40	F	NH	B	Y	Y	N	N	1.10
>30-35	F	H	W	Y	N	N	N	1.00
>35-40	F	NH	B	Y	N	N	N	0.90
>55-60	F	NH	W	N	N	N	N	0.80
>35-40	F	NH	B	Y	Y	Y	N	0.80
>30-35	F	NH	A	N	Y	N	N	0.72
>35-40	F	NH	A	N	Y	Y	N	0.70
>35-40	F	H	W	N	Y	Y	N	0.60
>35-40	F	NH	B	Y	Y	N	N	0.60
>45-50	F	NH	B	Y	Y	Y	N	0.60
>35-40	F	NH	A	Y	Y	N	N	0.60
>30-35	F	NH	A	N	Y	N	N	0.60
>25-30	F	NH	W	N	N	N	N	0.50
>30-35	F	H	W	Y	Y	Y	N	0.50
>20-25	F	NH	B	Y	N	Y	N	0.50
>35-40	F	H	W	Y	Y	Y	N	0.49
>50-55	F	NH	B	Y	Y	Y	N	0.40
>20-25	F	NH	B	Y	N	N	N	0.40
>25-30	F	NH	B	Y	Y	Y	N	0.40
>30-35	F	H	O	Y	N	N	N	0.37
>40-45	F	NH	W	Y	N	N	N	0.30
>65-70	F	NH	W	N	Y	N	N	0.30
>50-55	F	H	B	Y	N	Y	N	0.30
>60-65	F	NH	B	Y	N	N	N	0.30
>25-30	F	NH	W	N	N	N	N	0.30
>30-35	F	H	B	Y	Y	Y	N	0.22
>40-45	F	NH	W	Y	Y	Y	N	0.20
>45-50	F	NH	W	N	N	Y	N	0.20
>40-45	F	NH	A	Y	N	N	N	0.20
>25-30	F	NH	A	Y	Y	N	N	0.20

>25-30	M	H	W	Y	Y	Y	N	0.20
>55-60	F	H	W	Y	N	N	N	0.20
>55-60	F	NH	W	N	Y	Y	N	0.20
>45-50	F	NH	B	Y	N	N	N	0.20
>30-35	F	NH	B	Y	Y	N	N	0.20
>55-60	F	NH	W	Y	Y	N	N	0.20
>50-55	M	NH	B	Y	N	N	N	0.20
>30-35	F	NH	W	N	Y	N	N	0.20
>20-25	F	NH	A	Y	Y	Y	N	0.20
>50-55	M	NH	A	Y	Y	Y	N	0.15
>35-40	F	H	W	Y	Y	Y	N	0.13
>25-30	F	H	W	N	N	N	N	0.11
>45-50	F	NH	B	N	Y	N	N	0.10
>45-50	F	H	O	N	N	N	N	0.10
>25-30	F	NH	B	Y	Y	N	N	0.10
>40-45	F	H	W	Y	N	N	N	0.10
>35-40	M	H	W	Y	Y	N	N	0.10
>45-50	F	NH	B	Y	N	N	N	0.10
>25-30	F	NH	W	Y	N	N	N	0.10
>70-75	F	NH	B	N	N	N	N	0.10
>40-45	F	NH	W	Y	N	N	N	0.10
>50-55	F	NH	A	Y	N	N	N	0.10
>45-50	F	H	W	N	Y	Y	N	0.10
>60-65	M	NH	W	Y	N	Y	N	0.10
>50-55	F	H	W	Y	N	N	N	0.10
>45-50	F	NH	A	Y	N	N	N	0.10
>40-45	F	NH	W	Y	N	N	N	0.10
>60-65	F	NH	W	Y	N	N	N	0.10
>40-45	F	NH	A	Y	Y	N	N	0.10
>55-60	F	NH	W	Y	Y	Y	N	0.10
>55-60	F	NH	B	Y	N	N	N	0.10
>40-45	F	NH	W	N	N	N	N	0.10
>50-55	F	NH	W	Y	N	Y	N	0.10
>25-30	F	NH	B	N	Y	N	N	0.10
>25-30	F	NH	A	Y	Y	N	N	0.10
>50-55	F	NH	B	Y	N	N	N	0.10
>30-35	F	NH	O	Y	Y	Y	N	0.10
>55-60	F	NH	A	Y	N	N	N	0.10
>20-25	F	NH	B	N	N	Y	N	0.10
>20-25	F	NH	A	Y	Y	N	N	0.10
>30-35	F	NH	B	Y	Y	N	N	0.10
>25-30	F	H	W	Y	Y	N	N	0.10

>25-30	F	NH	A	Y	Y	Y	N	0.10
>60-65	M	NH	W	Y	Y	N	N	0.10
>30-35	F	NH	B	Y	Y	N	N	0.10
>20-25	F	NH	W	Y	Y	N	N	0.10
>45-50	F	NH	B	Y	N	N	N	0.10
>30-35	F	NH	W	Y	N	N	N	0.10
>25-30	F	H	W	Y	N	Y	N	0.10
>60-65	F	NH	B	N	N	N	N	0.10
>45-50	F	NH	B	Y	N	N	N	0.10
>30-35	F	NH	B	Y	Y	N	N	0.10
>40-45	F	H	B	Y	N	N	N	0.10
>50-55	F	H	W	Y	Y	N	N	0.10
>60-65	F	NH	W	N	N	N	N	0.10
>55-60	F	NH	W	Y	Y	Y	N	0.10
>55-60	F	NH	W	Y	Y	N	N	0.10
>25-30	F	NH	W	Y	N	N	N	0.10
>20-25	F	NH	W	Y	Y	N	N	0.10
>20-25	F	H	W	Y	N	Y	N	0.10
>25-30	F	NH	A	Y	Y	Y	N	0.10
>30-35	F	NH	B	Y	Y	Y	N	0.10
>50-55	F	NH	W	Y	N	Y	N	0.10
>60-65	F	NH	W	N	N	N	N	0.10
>20-25	F	NH	B	Y	N	N	N	0.10
>55-60	F	NH	B	Y	Y	Y	N	0.10
>30-35	F	NH	B	Y	Y	N	N	0.10
>45-50	F	NH	B	Y	Y	Y	N	0.10
>50-55	M	NH	O	Y	Y	Y	N	0.10
>60-65	F	NH	A	Y	Y	N	N	0.09
>50-55	F	NH	B	Y	Y	N	N	0.08
>40-45	F	NH	B	Y	N	N	N	0.08
>40-45	F	NH	A	Y	Y	N	N	0.08
>65-70	F	NH	B	N	N	N	N	0.07
>45-50	F	NH	B	Y	N	Y	N	0.07
>45-50	F	NH	B	Y	Y	N	N	0.05
>60-65	F	H	B	Y	N	N	N	0.04
>30-35	F	NH	A	N	N	N	N	0.04
>20-25	F	H	W	Y	Y	N	N	0.04
>50-55	F	H	W	N	N	N	N	0.04
>20-25	M	NH	B	Y	Y	N	N	0.04
>50-55	F	H	W	Y	Y	Y	N	0.04
>50-55	F	H	W	Y	N	Y	N	0.03
>65-70	M	NH	B	Y	N	N	N	0.03

>30-35	F	NH	A	Y	Y	N	N	0.03
>45-50	F	H	W	N	N	N	N	0.02
>65-70	F	H	W	Y	N	N	N	0.02
>50-55	F	NH	B	Y	N	N	N	0.02
>70-75	F	H	W	Y	N	N	N	0.02
>70-75	F	NH	A	N	N	N	N	0.02
>55-60	F	NH	A	Y	Y	N	N	0.02
>20-25	F	NH	B	Y	N	N	N	0.01
>50-55	F	NH	B	N	Y	N	N	0.01
>35-40	F	NH	A	Y	N	N	N	0.00
>30-35	F	NH	B	Y	Y	N	N	0.00
>40-45	F	NH	B	Y	Y	N	N	0.00
>25-30	F	NH	W	Y	Y	Y	N	0.00
>55-60	F	NH	O	N	N	N	N	0.00
>50-55	F	NH	B	Y	Y	N	N	0.00
>55-60	F	NH	W	N	Y	N	N	0.00
>60-65	F	NH	B	Y	N	N	N	0.00
>35-40	F	NH	B	Y	Y	N	N	0.00
>30-35	F	NH	W	Y	Y	N	N	0.00
>30-35	F	H	O	Y	N	N	N	0.00
>30-35	F	NH	B	Y	N	Y	N	0.00
>70-75	F	NH	W	Y	N	N	N	0.00
>45-50	F	H	W	N	Y	N	N	0.00
>55-60	F	NH	W	N	N	N	N	0.00
>65-70	F	H	B	N	Y	N	N	0.00
>40-45	F	H	W	N	Y	Y	N	0.00
>50-55	F	NH	A	N	Y	Y	N	0.00
>60-65	F	NH	B	Y	N	Y	N	0.00
>45-50	F	NH	W	Y	Y	N	N	0.00
>40-45	F	H	W	Y	Y	N	N	0.00
>65-70	M	NH	B	N	N	N	N	0.00
>50-55	F	NH	W	Y	N	N	N	0.00
>40-45	F	H	W	Y	Y	Y	N	0.00
>20-25	F	NH	B	Y	Y	Y	N	0.00
>35-40	F	H	W	Y	N	N	N	0.00
>40-45	M	NH	A	Y	N	N	N	0.00
>65-70	F	NH	W	N	N	N	N	0.00
>30-35	M	NH	W	Y	Y	Y	N	0.00
>65-70	F	NH	W	Y	N	N	N	0.00
>40-45	F	NH	B	N	N	N	N	0.00
>25-30	F	NH	B	Y	Y	N	N	0.00
>50-55	F	NH	B	Y	N	N	N	0.00

>75-80	F	NH	W	Y	Y	Y	N	0.00
>35-40	F	H	W	Y	N	N	N	0.00
>50-55	F	NH	B	Y	N	N	N	0.00
>30-35	F	NH	W	Y	Y	Y	N	0.00
>50-55	F	H	W	Y	Y	N	N	0.00
>25-30	F	NH	A	Y	Y	N	N	0.00
>25-30	F	H	O	Y	Y	N	N	0.00
>60-65	F	NH	A	Y	N	N	N	0.00
>60-65	F	NH	W	Y	Y	N	N	0.00
>60-65	F	NH	B	Y	Y	N	N	0.00
>45-50	F	NH	B	Y	N	N	N	0.00
>30-35	F	H	W	N	Y	N	N	0.00
>25-30	F	H	W	Y	Y	Y	N	0.00
>65-70	F	NH	W	Y	Y	N	N	0.00
>25-30	F	NH	B	Y	Y	N	N	0.00
>65-70	F	NH	B	Y	N	N	N	0.00
>40-45	F	H	W	Y	Y	Y	N	0.00
>30-35	F	NH	W	Y	N	N	N	0.00
>60-65	F	NH	W	Y	N	N	N	0.00
>35-40	F	NH	B	Y	N	N	N	0.00
>30-35	F	NH	B	Y	Y	N	N	0.00
>50-55	F	H	W	Y	Y	N	N	0.00
>20-25	F	NH	B	Y	Y	N	N	0.00
>45-50	F	NH	B	N	Y	Y	N	0.00
>30-35	F	NH	W	Y	Y	Y	N	0.00
>40-45	F	NH	A	Y	Y	Y	N	0.00
>20-25	M	NH	B	Y	Y	Y	N	0.00
>70-75	F	NH	B	Y	N	N	N	0.00
>45-50	F	NH	A	Y	N	N	N	0.00
>25-30	F	NH	W	Y	Y	Y	N	0.00
>20-25	F	NH	W	Y	N	N	N	0.00
>40-45	F	NH	A	Y	N	N	N	0.00
>20-25	F	NH	B	Y	Y	N	N	0.00
>35-40	F	NH	B	Y	N	N	N	0.00
>20-25	F	NH	W	Y	N	N	N	0.00
>50-55	F	NH	A	Y	Y	N	N	0.00
>35-40	F	NH	W	Y	N	N	N	0.00
>30-35	F	H	W	Y	Y	N	N	0.00
>35-40	F	H	O	Y	N	N	N	0.00
>25-30	F	NH	B	Y	Y	Y	N	0.00
>20-25	F	NH	B	N	Y	N	N	0.00
>25-30	F	NH	W	Y	Y	N	N	0.00

>20-25	F	NH	W	Y	Y	Y	N	0.00
>30-35	F	NH	A	Y	Y	N	N	0.00
>60-65	F	NH	W	Y	N	N	N	0.00
>65-70	F	NH	W	Y	N	N	N	0.00
>40-45	F	H	O	Y	N	N	N	0.00
>20-25	F	NH	B	Y	Y	Y	N	0.00
>30-35	F	NH	W	Y	N	N	N	0.00
>45-50	F	H	B	Y	Y	N	N	N/A
>35-40	F	NH	A	Y	N	Y	Y	N/A
>30-35	F	NH	A	Y	Y	Y	Y	N/A
>25-30	F	NH	W	Y	N	N	Y	N/A
>45-50	F	NH	W	N	N	N	Y	N/A
>40-45	F	NH	W	Y	Y	N	Y	N/A
>35-40	F	NH	W	Y	N	Y	Y	N/A
>50-55	M	NH	B	Y	N	N	Y	N/A
>30-35	F	NH	B	N	N	N	Y	N/A
>20-25	F	H	W	Y	Y	N	Y	N/A
>40-45	F	H	O	Y	Y	N	N	N/A
>35-40	F	NH	W	Y	N	N	N	N/A
>25-30	F	H	W	Y	Y	N	N	N/A
>20-25	F	H	O	Y	Y	Y	N	N/A
>35-40	F	H	B	Y	Y	N	N	N/A
>35-40	F	H	O	Y	Y	N	N	N/A
>35-40	F	NH	B	Y	N	Y	N	N/A
>30-35	F	NH	B	Y	N	N	N	N/A
>35-40	F	NH	A	Y	N	N	N	N/A
>60-65	F	H	O	Y	Y	Y	N	N/A
>40-45	F	H	O	Y	Y	N	N	N/A
>25-30	F	H	O	Y	Y	Y	N	N/A
>25-30	F	NH	B	Y	Y	N	N	N/A
>35-40	F	NH	W	Y	Y	Y	N	N/A
>35-40	F	NH	A	Y	Y	N	N	N/A
>25-30	F	NH	W	Y	N	N	N	N/A
>30-35	F	NH	B	Y	Y	Y	N	N/A
>35-40	F	NH	O	Y	Y	N	N	N/A
>55-60	F	NH	O	Y	Y	Y	N	N/A
>75-80	F	NH	W	Y	Y	N	N	N/A
>50-55	F	NH	W	N	Y	N	N	N/A
>40-45	F	NH	O	Y	N	N	N	N/A
>60-65	F	NH	W	N	N	N	N	N/A
>30-35	F	NH	B	Y	N	N	N	N/A
>30-35	F	NH	A	Y	N	N	N	N/A

>35-40	F	NH	W	Y	Y	N	N	N/A
>25-30	F	H	W	Y	Y	N	N	N/A
>40-45	F	NH	W	Y	N	N	N	N/A
>25-30	F	H	W	Y	Y	N	N	N/A
>55-60	F	H	W	N	Y	Y	N	N/A
>55-60	F	NH	W	Y	Y	N	N	N/A
>55-60	F	NH	W	Y	Y	N	N	N/A
>40-45	F	NH	W	Y	N	N	N	N/A
>45-50	F	NH	B	Y	N	N	N	N/A
>35-40	F	NH	W	Y	Y	N	N	N/A
>25-30	F	NH	W	N	N	Y	N	N/A
>55-60	F	H	B	Y	N	Y	N	N/A
>80-85	F	NH	W	N	Y	N	N	N/A
>30-35	F	NH	B	N	Y	Y	N	N/A
>30-35	F	NH	B	Y	Y	Y	N	N/A
>50-55	F	NH	W	Y	N	N	N	N/A
>40-45	F	NH	A	Y	N	N	N	N/A
>25-30	F	NH	W	Y	N	N	N	N/A
>45-50	F	NH	B	Y	Y	N	N	N/A
>35-40	F	H	W	Y	Y	Y	N	N/A
>35-40	F	NH	A	Y	N	N	N	N/A
>30-35	F	NH	O	Y	Y	Y	N	N/A
>25-30	F	H	W	Y	Y	N	N	N/A
>25-30	F	NH	B	Y	Y	Y	N	N/A
>40-45	M	NH	B	Y	Y	N	N	N/A
>45-50	F	NH	A	Y	N	N	N	N/A
>25-30	F	NH	A	Y	Y	Y	N	N/A
>60-65	F	NH	W	Y	N	N	N	N/A
>50-55	F	NH	A	Y	Y	Y	N	N/A
>35-40	F	H	W	Y	Y	Y	N	N/A
>40-45	F	NH	A	Y	Y	Y	N	N/A
>40-45	F	H	W	Y	N	Y	N	N/A
>35-40	F	NH	W	Y	Y	N	N	N/A
>40-45	F	NH	A	N	N	Y	N	N/A
>35-40	M	NH	A	Y	N	Y	N	N/A
>30-35	F	NH	A	N	Y	Y	N	N/A
>45-50	F	NH	A	N	Y	Y	N	N/A
>20-25	F	H	O	Y	Y	N	N	N/A
>40-45	F	NH	A	Y	N	Y	N	N/A

A, Asian race; Ab, Antibody; B, Black race; F, Female; H, Hispanic; HCQ, Hydroxychloroquine; IS, Immunosuppressant; M, Male; N/A, not available; NH, Not Hispanic; O, Other race; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S/c, Specimen calibrator; SLE, Systemic Lupus Erythematosus; W, White race.